Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pharmaceutical statistics

Showing results (81-90 of 1,235) with videos related to

Pageof 124
Sort By:
Pharmaceutical Statistics|January 20, 2023
Improving early phase oncology clinical trial design: The case for finding the optimal biological doseAlan Phillips, Shalini Mondal
Pharmaceutical Statistics|November 10, 2018
Calculation of confidence intervals for a finite population sizeSteven A Julious
Pharmaceutical Statistics|November 10, 2018
A simple test for the treatment effect in clinical trials with a sequential parallel comparison design and negative binomial outcomesGosuke Homma, Takashi Daimon
Pharmaceutical Statistics|October 22, 2016
Accounting for uncertainty in the historical response rate of the standard treatment in single-arm two-stage designs based on Bayesian power functionsFrancesca Matano, Valeria Sambucini
Pharmaceutical Statistics|December 6, 2016
Α Markov model for longitudinal studies with incomplete dichotomous outcomesOrestis Efthimiou, Nicky Welton, Myrto Samara, et al.
Pharmaceutical Statistics|December 10, 2016
Model averaging for treatment effect estimation in subgroupsBjörn Bornkamp, David Ohlssen, Baldur P Magnusson, et al.
Pharmaceutical Statistics|November 29, 2016
Application of Bayesian hierarchical models for phase I/II clinical trials in oncologyShinjo Yada, Chikuma Hamada
Pharmaceutical Statistics|December 15, 2016
Misspecification of at-risk periods and distributional assumptions in estimating COPD exacerbation rates: The resultant bias in treatment effect estimationM Law, M J Sweeting, G C Donaldson, et al.
Pharmaceutical Statistics|January 31, 2017
Robust inference for group sequential trialsJitendra Ganju, Yunzhi Lin, Kefei Zhou
Pharmaceutical Statistics|March 23, 2019
Commentary on: Subgroup analysis and interpretation for phase 3 confirmatory trials: White Paper of the EFSPI/PSI working group on subgroup analysis by Dane, Spencer, Rosenkranz, Lipkovich, and ParkeRobert Hemmings, Armin Koch
Pageof 124

Showing results (81-90 of 1,235) with videos related to

Sort By:
Pageof 124
Pharmaceutical Statistics|January 20, 2023
Improving early phase oncology clinical trial design: The case for finding the optimal biological doseAlan Phillips, Shalini Mondal
Pharmaceutical Statistics|November 10, 2018
Calculation of confidence intervals for a finite population sizeSteven A Julious
Pharmaceutical Statistics|November 10, 2018
A simple test for the treatment effect in clinical trials with a sequential parallel comparison design and negative binomial outcomesGosuke Homma, Takashi Daimon
Pharmaceutical Statistics|October 22, 2016
Accounting for uncertainty in the historical response rate of the standard treatment in single-arm two-stage designs based on Bayesian power functionsFrancesca Matano, Valeria Sambucini
Pharmaceutical Statistics|December 6, 2016
Α Markov model for longitudinal studies with incomplete dichotomous outcomesOrestis Efthimiou, Nicky Welton, Myrto Samara, et al.
Pharmaceutical Statistics|December 10, 2016
Model averaging for treatment effect estimation in subgroupsBjörn Bornkamp, David Ohlssen, Baldur P Magnusson, et al.
Pharmaceutical Statistics|November 29, 2016
Application of Bayesian hierarchical models for phase I/II clinical trials in oncologyShinjo Yada, Chikuma Hamada
Pharmaceutical Statistics|December 15, 2016
Misspecification of at-risk periods and distributional assumptions in estimating COPD exacerbation rates: The resultant bias in treatment effect estimationM Law, M J Sweeting, G C Donaldson, et al.
Pharmaceutical Statistics|January 31, 2017
Robust inference for group sequential trialsJitendra Ganju, Yunzhi Lin, Kefei Zhou
Pharmaceutical Statistics|March 23, 2019
Commentary on: Subgroup analysis and interpretation for phase 3 confirmatory trials: White Paper of the EFSPI/PSI working group on subgroup analysis by Dane, Spencer, Rosenkranz, Lipkovich, and ParkeRobert Hemmings, Armin Koch
Pageof 124